CD19 and diffuse large B-cell lymphoma: The suitability of PBD dimers as ADC payloads is exemplified by the FDA approval of loncastuximab tesirine (Zynlonta®), an anti-CD19 ADC used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [40].